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THERAPEUTIC POTENTIAL OF RAD51 INHIBITION 
DOUGLAS LE 
ABSTRACT 
DNA provides the instructions and regulation of cell growth and survival. Mutations in 
DNA can cause uncontrolled and unregulated cell proliferation, resulting in cancer. 
Treatment of cancer involves physical removal of these cells through surgery or inducing 
cell death by causing irreversible damage to DNA through chemotherapy and 
radiotherapy. However, natural DNA repair mechanisms may interfere with therapy and 
may even be increased in cases of therapy resistant cancer. The use of chemotherapy and 
radiotherapy leads to increased recruitment of DNA repair proteins while aggressive, 
therapy resistant cancers show overexpression of DNA repair proteins. Rad51 is a protein 
involved in the homologous recombination (HR) DNA repair process. Rad51 is recruited 
to sites of DNA damage caused by double stranded breaks, often generated by 
chemotherapy and radiotherapy. It is expected that inhibition of Rad51 will impair the 
HR repair process while enhancing the effectiveness of chemotherapy and radiotherapy 
compared to conventional means. As a result, this literature review aims to identify and 
examine the drug inhibitors of Rad51 in order to demonstrate the potential viability of 
this novel treatment in a variety of cancers.  
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INTRODUCTION 
 
Cell Cycle Checkpoints 
DNA contains the set of instructions necessary for cellular functions and life. In 
order for human cells to grow and proliferate, they must progress through several cell 
cycle checkpoints such as G0, G1, S, G2 and M phase (9). During the G0 phase, the cell 
is stable and not actively dividing. In the G1 phase, the cell is growing and prepares and 
organizes DNA for duplication. S phase results in DNA duplication. G2 leads to 
reorganization of the cell. M phase refers to mitosis, which results in cell division and the 
formation of new cells. DNA damage will prevent the cell from advancing to the next 
checkpoint and will result in cell death through apoptosis or triggering DNA repair 
processes, potentially resulting in cell survival (12). As a result, the cell cycle 
checkpoints act as regulation for the growth and proliferation of new cells along with 
regulation of cell survival. These checkpoints have great implications for cancer. 
 
Cell Cycle Dysregulation 
 Cancer is the result of uncontrolled cell growth and division. Cells become 
cancerous when the cell cycle checkpoint is ignored and growth of these cells becomes 
unchecked and unregulated (12). Normal checkpoint mechanisms are ineffective and 
damaged, mutated, or defective DNA is allowed to pass. This can cause abnormal cell 
function or result in further mutations potentially causing greater proliferation of the 
cancerous cells (12). Apoptosis does not activate and the cells can form into a tumor or 
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cause accumulation of abnormal cells within the blood. This dysregulation results in 
pathology and can compromise the organs along with the host.  
 
Accumulated Cell Damage 
 Although cancerous cells can ignore cell cycle arrest signals even with DNA 
mutation or DNA damage, other apoptosis mechanisms can be triggered in the event of 
significant cell stress or DNA damage (15). Inducement of cell stress or DNA damage 
can overwhelm the ability of the cancerous cell to grow and proliferate by interfering 
with the cell machinery. This interference can be due to interaction with critical cell 
growth materials such as, DNA, RNA, or proteins, or due to interaction with signal 
transduction (15). The end goal is to generate significant damage to the cancerous cell in 
order to prevent it from functioning and proliferating. As a result, cancer therapies take 
advantage of this method through the use of chemotherapy or radiotherapy. 
 
Improving Effectiveness of Cancer Therapies 
 Chemotherapy and radiotherapy interfere with cell proliferation through induction 
of DNA damage, thus preventing the cell from replicating (15). While this may stop 
cancerous cells from growing and induce apoptosis, natural repair mechanisms may 
render it less effective. Inducing DNA damage through the formation of DNA double 
strand breaks (DSB) from ionizing radiation (IR) results in the recruitment of DNA 
Homologous Recombination (HR) repair mediators such as the Rad51 protein (27). Since 
the goal of chemotherapy and radiotherapy is to cause significant DNA damage, the 
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ability of cancerous cells to repair DNA damage would be expected to decrease the 
effectiveness of these types of therapies. As a result, direct or indirect suppression of 
DNA repair mechanisms, such as inhibition of Rad51, may be a valid avenue for 
improving these conventional therapies. 
 Inhibition of Rad51 has shown interesting results and promise in the improvement 
of cancer therapies. A study using antisense oligonucleotides, complementary sequences 
used to inhibit DNA, resulted in inhibition of cell proliferation and a 90% increase in 
radiosensitivity correlated with 99% decrease in levels of Rad51 mRNA and 90% 
decrease in Rad51 protein levels in normal mouse cells (35). This demonstrated a 
powerful mechanism for Rad51 inhibition and set the stage for testing in cancerous cells.  
However, it raised the question of how Rad51 inhibition would perform in cancerous 
cells and live animal models.  
The authors, Ohnishi and Taki, repeated the Rad51 antisense inhibition 
experiments using mouse glioma cells in culture and in an animal model while using 
normal neurons as controls (36). Their experiment revealed that in-vitro antisense 
inhibition of Rad51 decreased mRNA levels by 90% and protein levels by 70% in glioma 
cells, improved in-vitro and in-vivo radiation sensitivity by decreasing tumor survival, 
and improved survival rates in mice treated with radiation compared to control (36). 
These results on mRNA inhibition were similar to the last study but showed that 
antisense inhibition may not be as effective in practice. Despite these mixed but 
promising results, there was interest in finding out how Rad51 inhibition affected normal 
mouse neurons after being exposed to radiotherapy.  
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Most interestingly, the antisense oligonucleotides were tagged with florescent 
markers, which indicated limited visibility around normal tissue while the glioma cells 
became highly florescent. This implied that cancerous cells expressed more Rad51 
compared to normal cells and that normal tissues were spared from radiosensitizing 
effects. At that time, the mechanisms were unclear as to why normal tissues were spared 
but the authors stated that Rad51 levels were highest during G2 and S phase, proliferative 
phases of the cell cycle, which could have affected expression of Rad51 levels (36). This 
suggested that Rad51 activity has specific preferences based on the cell cycle. While 
these studies used antisense oligonucleotides as Rad51 inhibitors, there was a need to find 
drugs that targeted this process.  
It was discovered by Slupianek et al. that increased Rad51 levels and DSB repair 
were moderated by an oncogenic tyrosine kinase known as BCR/ABL in leukemia cell 
lines (31). The high levels of Rad51 and increased activity of DSB in those leukemia 
cells contributed to decreased efficacy and resistance to chemotherapy drugs such as 
cisplatin and mitomycin C (29).   As a result, the authors then repeated their experiment 
using Gleevec, an ABL tyrosine kinase inhibitor used in the treatment of leukemia. The 
experiment revealed that Gleevec decreased Rad51 levels in leukemia cells while 
restoring efficacy to cisplatin and mitomycin C (29). Consequently, Gleevec was tested in 
other types of cancers such as human gliomas cells. 
Gleevec was used on 2 different human glioma cell lines which resulted in 
decreased Rad51 mRNA and protein levels, prevented recruitment of Rad51 to sites of 
DSB caused by radiotherapy, and increased rates of radiotherapy-induced apoptosis while 
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sparing regular human fibroblast cell lines from these effects (29). These results using 
Gleevec with human glioma cells were similar to the antisense in-vitro and in-vivo 
experiments using mouse glioma cells. Both improved radiotherapy while sparing normal 
cells from the potentially damaging effects of radiosensitization by inhibiting HR repair.  
 
Specific Aims/Objectives 
Since these experiments have demonstrated promising results using novel 
techniques to improve chemotherapy and radiotherapy, the goal of this paper is to review 
primary literature in order to identify different mechanisms and methods to suppress 
RAD51, a protein involved in the recruitment of homologous recombination (HR) DNA 
repair machinery, highlight differences and inconsistencies with study design and 
analysis, demonstrate why inhibition of Rad51 is an appropriate target for the 
improvement of cancer therapies as a first line treatment, and suggest future directions for 
study. It is expected that decreasing the ability of the cell to repair DNA damage through 
Rad51 inhibition will render it more susceptible to radiotherapy and chemotherapy, thus 
improving the effectiveness of conventional treatment. This paper will focus on 
reviewing literature from similar studies to determine if the use of Rad51 inhibitors 
improves conventional therapeutics such as radiation therapy or chemotherapy. 
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CANCER THERAPIES AND THE ROLE OF DNA REPAIR 
 
Conventional Cancer Treatment 
 The usual avenues for treating cancer rely on four major types of treatment: 
surgery, radiotherapy, chemotherapy, or combination therapy. Surgery is based on 
physical removal of the tumor or cancerous cells. Radiotherapy involves the use of 
radiation to damage DNA and induce cell death. Ionizing radiation damages DNA by 
causing single stranded DNA breaks (SSB), double stranded DNA breaks (DSB), and 
DNA lesions, all of which can prevent cell growth, proliferation or cause cell death (41).  
Chemotherapy uses a molecular method to generate alkylation, addition of alkyl groups 
to DNA, causing DNA damage and cell death. Alkylating agents can damage DNA by 
causing base damage, lesions, formation of bulky adducts, crosslinking, along with SSB 
and DSB (16).  These methods cause DNA damage, resulting in inhibition of growth of 
rapidly dividing and proliferating cells and can induce apoptosis. Treatment using 
chemotherapy or radiotherapy generally causes DSB (8). While surgery, radiotherapy and 
chemotherapy are effective methods for treating cancer, a combination of these types of 
therapy or multimodal therapy has been demonstrated to be more effective in treating a 
wide variety of cancers. However, multimodal therapy is not well tolerated in older 
populations or patients with certain health conditions. As a result, it is necessary to 
identify methods that will increase the effectiveness of radiotherapy or chemotherapy 
while minimizing dosage or exposure to these therapies. Focusing on DNA repair 
mechanisms will provide new avenues for improvement. 
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DNA Repair 
 DNA repair has 2 main repair mechanisms, Non-Homologous End Joining Repair 
(NHEJ) and Homologous Recombination Repair (HR). NHEJ works at all phases of the 
cell cycle but is mostly active in the G1 phase while HR prefers the G2/S phases (8). 
Focusing on HR repair is important for improving cancer therapies. This is due to the fact 
that HR repairs DSB generated by chemotherapy and radiotherapy (16,17).,  There is 
evidence to show that radiotherapy and chemotherapy specifically trigger HR repair 
which causes recruitment of proteins involved with DNA repair. For example 
radiotherapy causes increased phosphorylation of histone H2AX, indicating DSB, while 
activating HR repair through increasing the expression and recruitment of Rad51 protein 
to the sites of DSB (27). This test was used in many studies to identify the presence of 
DNA damage and repair. Chemotherapy can also generate DSB but through different 
pharmacological mechanisms. As expected, there was increased HR repair and 
expression of Rad51 following chemotherapy (1). Since chemotherapy and radiotherapy 
are based on inflicting DNA damage through formation of DSB and HR is activated by 
these DSB, impairing HR through inhibition of Rad51 expression or association should 
increase the effectiveness of these modalities. 
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RATIONALE FOR TARGETING RAD51 
 
Inhibiting Rad51 and the HR repair process represents a potential and reasonable 
mechanism for targeted therapy. Rad51 protein serves as a critical part of the HR repair 
process. Rad51 protein is recruited to the nucleus and binds to sites of DSB in order to 
repair naturally accumulated damage or DSB caused by chemical, UV, or IR methods 
(14, 32). After induction of DSB, the damaged strands are separated into two single 
stranded DNA strands (ssDNA) which allows for Replication binding protein A (RPA) to 
bind (40). RPA is an ssDNA binding protein that serves as a dock for Rad52, a protein 
that stimulates and interacts with Rad51 and RPA (40). This allows for Rad51 to make 
contact with the ssDNA strands since it has specificity for double stranded DNA 
(dsDNA) without RPA (22). After Rad51 forms a nucleoprotein filament on the tail of 
the ssDNA strand, it participates in strand exchange with homologous dsDNA (40). This 
process is repeated with the other ssDNA strands, allowing the tails to serve as primers 
for DNA repair (Figure 1) (40). While it may be problematic to inhibit repair of naturally 
occurring DNA damage and possibly cause malignant mutations, the benefits of Rad51 
inhibition in cancer cells far outweigh the risk. This is due to the fact that Rad51 
inhibition provides the benefit of increasing therapeutic efficacy, overexpression of 
Rad51 leads to poorer outcomes, and Rad51 overexpression plays a critical role in 
metastasis. 
As mentioned in the introduction, the experiments using siRNA targeting mice 
glioma and Gleevec targeting human glioma cells demonstrated improved sensitivity to 
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radiation therapy and chemotherapy respectively. These experiments demonstrated the 
feasibility of targeting Rad51. Targeting Rad51 is further supported by numerous studies 
that have indicated that Rad51 may be overexpressed in cancerous cells and leads to poor 
outcomes for many different types of cancers such as colorectal, esophageal squamous 
cell carcinoma, cervical, and breast cancer.  
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Figure 1. Rad51 Repair of Double Stranded DNA Break (DSB). (Figure taken from 
West, et al., 2003) (40) 
A. DSB 
B.  Resection of DSB exposes two single stranded DNA (ssDNA) tails, which allows 
binding of replication protein A (RPA), a dock for Rad52 binding. Interaction with 
Rad52 allows Rad51 to bind the ssDNA-RPA unit. 
C. Rad51 forms a filament on the ssDNA tail, allowing the complex to participate in 
strand exchange with homologous double stranded DNA (dsDNA). 
D. The second ssDNA tail is recruited by Rad51 and/or Rad52. 
E. The tails serve as DNA primers for synthesis. 
F. Completed crossovers result in separation of the strands. 
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Different Cancers Show Elevated Rad51 
An immunohistochemistry analysis of 1200 colorectal cancers revealed that 54% 
of the biopsies were negative for Rad51 expression while the remaining 46% were 
categorized as weak (34%), moderate (11%), or strong (1%). The authors found that 
overall survival was significantly correlated with Rad51 expression (p=0.001), with 
median survival at 76 months for weak expression, 46 months for moderate, and 11 
months for strong (37). They also found that Rad51 expression was significantly 
correlated as an independent prognostic test (p = 0.011) along with predicting tumor stage 
and status (p < 0.0001) (37). These data indicate that increased Rad51 expression played 
an important role in overall survival, could be used as a prognostic marker, and targeted 
drug therapy might provide value to these patients.  
Analysis of post-surgical resection of 230 esophageal squamous cell carcinoma 
(ESCC) patients showed that nearly half of the patients (46.5%) showed high expression 
of Rad51 and these patients had statistically significant (p=0.034) decreased overall 
survival compared to those with low expression (61.6 months vs. 70.2 months) along 
with statistically significant (p = 0.031) decreased disease free survival (58.4 months vs 
67.7 months) (19). These data also indicated that increased Rad51 expression is 
correlated with poor outcomes compared to patients with decreased Rad51 expression. 
The data also showed that Rad51 was a statistically significant (p = 0.021 and p = 0.013) 
independent prognostic marker for overall survival and disease free survival (19). These 
results for ESCC are similar with colorectal cancers in correlating Rad51 expression with 
prognosis and patient survival. 
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Patients with cervical cancer may also benefit from Rad51 inhibition. Two groups 
of 21 undergoing mRNA study and 24 patients undergoing histological study with 
advanced cervical cancer were treated with combined chemoradiotherapy and selected for 
biopsy.  Half of these patients showed complete remission while the others had partial 
response. Patients with incomplete response to therapy showed significantly elevated 
levels of Rad51 mRNA and nuclear protein in the genomics group (p = 0.016) and 
histological group (p < 0.0001) (2). This study also showed that BRCA1, a protein that 
localizes with Rad51 and initiates DSB repair, was significantly elevated for patients with 
incomplete response in the genomics group (p = 0.032) and histological group (p < 
0.0001) (2). Elevation of Rad51 and BRCA1 levels appear to be prognostic indicators for 
whether or not a patient will have complete remission following treatment. As a result, 
cervical cancer patients with elevated levels of Rad51 would likely benefit from targeted 
inhibition.  
High levels of Rad51 were also discovered in breast cancer and significantly 
correlated with poorer outcomes. A study which examined biopsies from 75 patients 
found that high levels of Rad51 significantly correlated with estrogen receptor positive 
(ER) / progesterone receptor negative (PR) tumors (P = 0.03) and these types of tumors 
were identifiable on immunohistochemical analysis (p = 0.003) (4). Taken alone, these 
findings indicated that Rad51 expression and breast cancer subtype could be identified by 
histological examination by using Rad51 protein as a marker. But the authors also 
analyzed the microarray RNA from 295 patients and found that high levels of Rad51 led 
to elevated risk of relapse (p = 0.015), metastases (p = 0.009), and poorer survival (p = 
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0.013) while the PR positive subtype resulted in better prognosis (p = 0.015) (4). It is 
interesting to note that this study indicated that elevated levels of Rad51 may lead to 
metastasis. However, the mechanism was not identified. Combined with these data, 
histological analysis of Rad51 as a diagnostic marker could be a potential method for 
identifying specific breast cancer subtype that is likely to have poorer outcomes and 
would benefit from certain types of therapies, including Rad51 inhibition.  
 
Influence of Rad51 on Therapeutic Efficacy and Metastasis 
While the previous studies have correlated Rad51 overexpression with poorer 
outcomes, there is also indication that it may have a role in metastasis.  A study on 
esophageal squamous cell carcinoma (ESCC) examined the influence of Rad51 on 89 
patients who were treated with surgery and 39 patients who received neoadjuvant 
chemoradiotherapy, their first exposure, followed by surgery. The surgery only patients 
with high levels of Rad51 had significantly greater frequency of metastasis (p = 0.0168, 
58% vs. 30%) compared to those with low levels of Rad51 (23). Since these cells have 
not been treated and therefore accumulated therapy induced DSBs, it is likely that the 
elevation in Rad51 contributed to permitting cell survival in cells that have genetic 
irregularity. However, the mechanism for how this could lead to metastasis was not 
clarified in this article. Similar to other studies, elevated Rad51 led to significantly 
decreased frequency of therapeutic response for patients receiving neoadjuvant 
chemoradiotherapy compared to those with low expression of Rad51 (p = 0.0171, 46.5% 
vs. 68.8%) (23). Clearly, Rad51 overexpression reduced therapeutic efficacy for 
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chemoradiotherapy while those without overexpression showed better responsiveness. 
For these data, it is possible that Rad51 inhibition could result with a 20% increase in 
combined chemoradiotherapy efficacy and decreased frequency for metastasis in patients 
with ESCC by half.   
While previously mentioned studies demonstrated the correlation between Rad51 
overexpression and metastasis, the following study by Wiegmans et al. provided crucial 
insight on the mechanism for Rad51 on metastasis (42). Their immunohistochemistry 
analysis of 235 breast cancer tumor samples indicated that Rad51 overexpression 
correlated with metastatic status and high tumor grade along with identifying a 
mechanism by which Rad51 supports metastasis. Triple negative breast cancer tissue 
showed twice the amount of Rad51 protein compared to normal tissue (Figure 2) (42). 
Invasive ductal carcinoma showed 3 times the frequency of Rad51 overexpression 
compared to invasive lobular carcinoma (p=0.0008, 26% vs. 9%) (Figure 2) (42). Tumor 
progression data from 23 patients were matched to progression of ductal carcinoma in-
situ to lymph node metastasis showed that increasing tumor severity correlated with 
higher frequency of Rad51 overexpression (Figure 2) (42). Patients matched to 
progression of invasive lobular carcinoma to lymph node metastasis and primary invasive 
ductal carcinoma to brain metastasis also showed the same correlation (Figure 2) (42). 
These data reveal that certain subsets of breast carcinomas are more prone to Rad51 
overexpression, which correlated with increased severity and frequency of metastasizing.  
In order to determine the role of Rad51 on metastasis, 4T1.2 cells, a type of 
mammary carcinoma prone to metastasis in mice, were implanted in vivo and Rad51 was 
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silenced using small hairpin RNA (shRNA). Use of Rad51 silencing in 4T1.2 cells 
resulted with significantly decreased tumor growth rate (p=0.0013) and metastasis 
compared to controls not receiving shRNA (Figure 3C) (42). This provided evidence that 
Rad51 demonstrated great influence over tumor progression. However, Rad51 inhibition 
through shRNA decreased tumor growth rate and decreased maximum volume by a 
fourth, highlighting the great benefit of targeting this mechanism and possibly including 
it with conventional therapies.  
This experiment was repeated following resection of the primary tumors and 
Rad51 silenced mice showed delay in primary tumor regrowth while control mice 
showed metastasis of secondary tumors (Figure 3D) (42). Both experiments with shRNA 
indicated that Rad51 overexpression is responsible for faster tumor growth and required 
for metastasis to occur. This is critical since the ability of inhibiting Rad51 could stop this 
type of aggressive progression. 
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Figure 2. Rad51 Expression and Tumor Progression 
(Figure taken from Wiegmans, et al., 2014) (42) 
A. Triple negative tumors marked with asterisk compared to unmarked normal tissue. 
Shows increased Rad51 expression in triple negative breast cancers. 
B. Immunohistochemistry microarray of 235 tumors demonstrating increased 
frequency of Rad51 overexpression correlating with tumor severity. 
C. Histological Evaluation of Rad51 Expression 
 Left: Primary breast carcinoma 
 Right: Metastatic carcinoma showing increased Rad51 expression 
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Figure 3. Relief of Metastatic Effects from Rad51 Silencing in 4T1.2 Breast 
Carcinoma Cells 
(Figure taken from Wiegmans, et al., 2014) (42) 
A. Exposure to Doxycycline triggers shRNA silencing of Rad51 after 48 hours in 
4T1.2 carcinoma cells compared to control. 
 
B. Both types of cells were viable after 7 days  
 
C. Indication that that shRNA induced by Doxycycline resulted with decreased 
rate of tumor growth 
 
D. Comparison of Rad51 silenced 4T1.2 to control revealed massively decreased 
occurrence of distal metastasis. 
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The question of how Rad51 overexpression is responsible for metastasis can be 
answered by a different experiment using metastatic human breast cancer cells, MDA-
MB-231. Implantation of MDA-MB-231 cells into mouse lungs showed that the mice 
treated with shRNA did not display in metastasis while over half of the control mice had 
metastasis in distal organs (Figure 4) (42). It appeared that Rad51 was required for 
implantation and colonization at distal sites. Wiegmans et al. analyzed Rad51 silenced 
cells and found that morphology indicated that although there was a metastatic-like 
change from mesenchymal to epithelial, there were no changes in stem cell markers or 
cell adhesion proteins required for colonization (42). They confirmed these data by 
repeating the experiment with Rad51 overexpressed BT549 breast cancer cells which 
resulted in metastasis and increased expression of stem cell markers and cell adhesion 
proteins (42). These interesting results indicate that Rad51 overexpression is responsible 
for molecular and structural transformations that allow the carcinoma to colonize and 
metastasize in distal organs while silenced cells prevent this effect. Genetic analysis of 
Rad51 silenced cells showed decreased expression of genes responsible for metastatic 
proliferation and invasion along with decreased expression of genes that play a role in 
regulation of mammary gland development, such as c/EBPβ (42). This study on breast 
cancer metastasis has been crucial in identifying the role that Rad51 plays in metastatic 
tumor implantation and colonization, morphological changes that support distal 
metastasis, and genetic influence on dysregulation of normal growth processes. Hopefully 
this evidence will spawn further study and analysis. 
 
 19 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Requirement of Rad51 for Metastasis in MDA-MB-231 Human Breast 
Carcinoma Cells 
(Figure taken from Wiegmans, et al., 2014) (42) 
A. Exposure to Doxycycline triggers shRNA silencing of Rad51 after 24 hours. 
B. In vitro analysis of cell growth and viability between Rad51 knockout and 
control showed lack of significant effect. 
C. Rad51 silenced cells showed decreased rate of tumor growth compared to 
control. 
D. Rad51 silenced cells show no distal metastasis compared to over 50% 
metastasis in control after day 14. 
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The rationale for targeting Rad51 has been highlighted by studies which indicated 
that Rad51 influenced therapy outcome by affecting therapeutic efficacy, it has been 
overexpressed in a wide variety of tumor types compared to normal cells, and it 
influences metastatic progression and lethality. Influence on therapeutic efficacy was 
demonstrated with Rad51 overexpression and activation of HR repair at sites of DSB 
caused by therapeutic intervention. Studies using siRNA or pharmacological intervention 
provided evidence of increased therapeutic efficacy and apoptotic activity through Rad51 
inhibition. Since it was demonstrated that Rad51 was overexpressed in many types of 
cancers while not overexpressed in regular cells, this provided the basis for safely 
targeting cancer specific cells while sparing healthy cells. The fact that these studies also 
showed statistically significant correlation of Rad51 overexpression with disease 
progression and utility as a prognostic marker highlight the value of performing more 
studies analyzing the role of Rad51. Most importantly, Rad51 overexpression has been 
shown to be required for metastatic progression and significantly correlated with 
increased frequency of metastasis and cellular changes required for metastasis. These 
factors combined provide logical evidence for targeting Rad51 as a means to improve 
therapeutic efficacy and clinical outcomes in cancer patients. As a result, the remainder 
of the paper will focus on literature reviews of published studies to in order to determine 
which Rad51 inhibitors exist and the performance of these inhibitors in various in vitro 
and in vivo models along with highlighting areas of concerns and future directions.  
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Literature Review: Viability of Rad51 Inhibitors 
 
Published Studies: Existing Chemotherapeutic Inhibitors 
 
 After performing a literature review, there appear to be recent discoveries on the 
mechanisms of many existing chemotherapeutic interventions. These mechanisms have 
been identified as direct or indirect inhibitors of Rad51 function. Since it was understood 
that Rad51 inhibition may increase sensitivity to chemotherapy and radiotherapy along 
with preventing or halting metastasis, these agents were tested in a wide variety of 
cancers and models to determine efficacy. The results were very promising. There are 
also new experimental inhibitors that directly target Rad51 and these results will be 
summed as well. Most interestingly, researchers may have discovered a way to deliver 
targeted gene therapy to inhibit Rad51 only in carcinomas while sparing normally 
functioning cells. This may result in greater benefit compared to pharmacological 
delivery. 
Data 
Erlotinib 
Erlotinib is a tyrosine kinase inhibitor of EGFR, epidermal growth factor receptor, 
which has shown to be upregulated in head and neck squamous cell carcinoma (SCC) and 
non-small cell lung cancer (NSCLC) and leads to poorer outcomes, decreased therapeutic 
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efficacy, and radiation resistance (7).  Studies showed that EGFR mediates signaling of 
DNA dependent protein kinase (DNA-PK), which is required for activation of HR and 
NHEJ DSB repair (3). This study examined Erlotinib treatment alone, x-ray therapy alone 
or combination of Erlotinib and X-ray therapy in in-vitro and in-vivo models for human 
NSCLC, prostate cancer cells, and human head-and-neck SCC.  
In-vitro use of Erlotinib showed inhibition of radiotherapy induced activation of 
EGFR, inhibited expression of Rad51 protein, increased radiosensitivity and decreased 
carcinoma cell survival (7).  Tests using Human Non-Small Cell Lung Carcinoma (H226) 
and Human head-and-neck Squamous Cell Carcinoma (UM-SCC1) showed that Erlotinib 
and radiation combined resulted in a 35% to 75% increase in apoptosis compared to 
Erlotinib alone (10% to 25%) or radiation alone (25% to 50%) (7). This increase was 
additive, which demonstrated the strength of combined therapy compared to 
monotherapy (7). Erlotinib prevented activation of EGFR receptor after radiation 
exposure, potentially minimizing the risk of radiation-induced regrowth of cancer cells 
(7). Erlotinib successfully prevented an increase in Rad51 expression after radiation 
exposure while irradiated cells showed elevated Rad51 expression (7). After exposure to 
increasing doses of radiation, Erlotinib moderately increased radiation response by 
decreasing cell survival by 10% at all radiation doses compared to controls (7).  
In-vivo study of these tumors in mouse xenographs revealed that combination 
therapy was superior to Erlotinib or x-ray therapy alone and histological analysis favored 
combination therapy (7). Further studies using in-vivo xenographs of both cell lines 
showed that after 60 days, Erlotinib alone decreased tumor volume by 20%, radiation 
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therapy alone decreased tumor volume by 50% compared to controls, and Erlotinib + 
radiation therapy was superior at decreasing tumor volume by 75% with statistical 
significance (7). Histological study of in-vivo lung cell carcinoma growth showed that 
combination therapy demonstrated the least staining of tumor proliferation markers and 
EGFR markers, monotherapy groups (radiation alone or Erlotinib alone) showed 
moderate levels of staining, and untreated controls showed the most amount of staining 
(7). 
Imatinib 
Imatinib inhibits several tyrosine kinases but most importantly it inhibits c-ABL, 
a regulator for increasing Rad51 expression and formation around DSB (8). In-vitro 
studies were performed on normal fibroblast  (GM05757), prostate adenocarcinoma 
(PC3), pancreatic adenocarcinoma (PANC1), bladder carcinoma (RT112M), and human 
lung carcinoma (H1299-DR-GFP) cell lines. Evidence showed a 40 to 50 percent 
decrease in Rad51 expression, 60 to 70 percent decrease in HR repair efficacy, and 
decreased association of Rad51 at the sites of DSB that were independent of the cell 
cycle (8). Interestingly there was only a 30 to 40 percent decrease in HR repair efficacy 
with siRNA (8). In-vitro studies demonstrated that multimodal therapy was more 
effective in causing mitotic catastrophe than monotherapy due to increased 
chemosensitivity and radiosensitivity along with decreased cell survival in tumors but not 
in fibroblasts (9). The in-vivo study using mouse prostate adenocarcinoma xenographs 
showed great clinical practicality for using Imatinib combined with radiation. Those 
results showed that Imatinib with radiotherapy improved the delay in tumor growth after 
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exposure to radiation compared to controls using radiation alone or Imatinib alone (8). 
Tests of mice weight and post-mortem histological study of the gut lining showed that 
weight and gut toxicity were comparable to irradiated controls (8). 
Panobinostat 
Panobinostat is a histone deacetylase inhibitor (HDACi) that suppresses tumor 
growth by modifying chromatin access along with affecting transcription, signaling, and 
DNA repair proteins (13). The author’s goal was to examine the role of Panobinostat on 
HR repair proteins on muscle invasive bladder cancer cells (RT112) in combination with 
radiotherapy and with radiotherapy alone. They found that nanomolar amounts of 
Panobinostat were effective for downregulation of Rad51 and other HR repair signaling 
proteins such as MRE11 and NSB without affecting Ku70 or Ku80, NHEJ repair proteins 
(13). Controls did not show downregulation. Compared to untreated cells, Panobinostat 
increased tumor kill rates and decreased Rad51 protein levels, which were found to 
correlate with delayed γH2AX foci formation following ionizing radiation therapy (13). 
SAHA 
Suberoylanilide Hydroxamic Acid (SAHA) is another HDACi that is approved for 
treatment of T-cell lymphoma by impairing HR repair through modification of chromatin 
structure (6). The change in histone modification prevents Rad51 from accessing DSB 
and affects signaling processes independent of the cell cycle (6). These experiments 
demonstrated decreased cell survival following radiotherapy, increased and sustained 
γH2AX foci, and resulted in a 3-fold decrease in Rad51 levels along with reduced Rad51 
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binding to γH2AX foci. The massive decrease in functional Rad51 protein and prevention 
of Rad51 binding to sites of DSB are likely to be responsible for the decreased survival 
which were also seen in tests using human multiple myeloma cell lines (MM1.s, U226B1, 
RPMI8226, KMS-11) when combined with exposure to radiotherapy (Figure 5B) (page 
25) (6). 
There is clear indication that SAHA + radiotherapy is superior to monotherapy 
radiation.  Cyclin A levels, a marker for G2/S cycles which are preferred by Rad51, 
remained consistent between controls and SAHA treated cells in all 4 cell lines which 
indicated that changes in Rad51 expression were not due to effects on the cell cycle (6). 
The authors provided further evidence showing that SAHA specifically inhibited HR 
repair through Rad51 depletion and by preventing Rad51 from associating with 
chromatin, which was indicated by increased histone acetylation (Figure 5A) (page 25) 
(6). 
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Figure 5. Chromatin Accessibility To Rad51 Influences Radiation Sensitivity. (Figure 
taken from Chen, et al, 2012) (6). 
A-Left: Increasing dosage of SAHA increases histone H4 acetylation. Right-
Acetylation increases histone folding compared to controls. 
B-SAHA increases radiation sensitivity at increasing radiation doses through 
decreasing cancer cell survival.  
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Methotrexate 
While previous articles either focused on depletion of Rad51 protein or inhibition 
of Rad51 assembly at sites of DSBs, use of a DNA synthesis inhibitor also decreased 
Rad51 formation and function. Methotrexate is a DNA synthesis inhibitor currently used 
in the therapy of various cancers such as acute lymphoblastic leukemia and osteosarcoma 
(11). The purpose of this study was to identify the mechanism between use of 
Methotrexate and inhibition of HR repair in Human Osteosarcoma Cell lines (HOS). 
Methotrexate is known as an inhibitor of dihydrofolate reductase, which decreases the 
amount of tetrohydrofolate required for DNA synthesis (11). Data from this study 
showed that Methotrexate decreased Rad51 mRNA transcripts which reduced Rad51 
protein levels thus preventing repair of DSBs through inhibition of HR repair (11). 
Rather than use γH2AX as a marker for unrepaired DSBs as in previous studies, 
the authors used comet assays to quantify the amount of DNA damage. Compared to 
HOS cells exposed only to radiation, Methotrexate in combination with ionizing radiation 
(IR) produced longer comet moments, indicating that there was twice the amount of DNA 
damage (11). Using a HR Repair Assay, an I-SceI endonuclease to induce DSBs, the 
authors showed that there was inverse correlation between length of comet moments and 
DSB repair efficiency (11).  
This raised the question of whether or not inhibition of DNA synthesis was the 
reason for this decrease in efficiency or if Methotrexate directly affected HR repair 
through Rad51. Testing showed that there was no antibody staining of Rad51 protein in 
Methotrexate treated with IR and there was a 100% decrease in Rad51 mRNA but lower 
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than 20% decrease in BRCA2 and Rad52 mRNA (11). NHEJ deficient HOS cells treated 
with increasing doses of Methotrexate showed vastly decreasing rates of colony 
formation with a maximum of twice the magnitude compared to wild type HOS cells 
(11). 
 
Experimental Rad51 Inhibitors 
IBR-2 
Mutations in upstream factors such as Bcr-abl, which is responsible for Rad51 
overexpression, can decrease Imatinib efficacy (44). As a result, the authors designed a 
study to identify small molecule inhibitors of Rad51 protein that would be effective 
against Imatinib resistant cancer. Their experimentation resulted in the discovery of IBR-
2, a small molecular inhibitor that binds directly to Rad51 protein. The molecule was 
designed with similarity to BRCA2 binding motifs (BRC motifs), a factor which Rad51 
binds to. The results revealed important and critical data. IBR-2 targeted a structure 
known as 1524-FHTASGK-1530 in order to prevent Rad51 protein from associating with 
BRC motifs, resulting in an attack on specific assembly sites (44). 
The authors used an I-SecI GFP to introduce DSBs. IBR-2 decreased the fraction 
of GFP positive cells, IBR-2 + ionizing radiation (IR) decreased Rad51 foci by half and 
greatly decreased colony survival with increasing doses of IR (44). Mechanistic study of 
IBR-2 action revealed interesting data. IBR-2 did not affect Rad51 mRNA levels but 
specifically decreased Rad51 protein levels (44). Other proteins, such as Rad50 and ERK, 
  29 
showed normal results indicating that IBR-2 specifically interfered with Rad51 protein 
formation which led to increased breakdown of Rad51 protein through increased 
proteasome activity (44). Use of a proteasome inhibitor proved this hypothesis correct 
since it resulted in increased Rad51 protein stability (44).  
Interference with Rad51 protein function and accelerated proteasome action also 
resulted with inhibition of cancer cell growth and increased cell death in many different 
cell lines such as human leukemia (K562), metastatic human breast cancer (MDA-MB-
231), triple negative human breast cancer (MDA-MB-468), estrogen responsive human 
breast cancer (MCF7), human ductal breast cancer (T47D), and human breast epithelial 
cells (HBL100) (44). Efficacy after 24 hours showed double the efficacy, which was 
attributed to accelerated proteasome activity (44). 
These results suggested that IBR-2 might show efficacy against in-vivo 
xenographs of mice using the Chronic Myeloid Leukemia cell lines (T315I) which are 
resistant to Imatinib and its second-generation tyrosine kinase inhibitors, Dasatinib and 
Nilotinib. IBR-2 decreased tumor growth and volume by 75% compared to control 
without side effects (44). Using Rad51 RNAi as an inhibitor to test for IBR-2 specificity 
showed similar outcomes. Tests of tolerability showed that IBR-2 did not significantly 
affect normal cord blood cells or bone marrow cells while decreasing multidrug resistant 
Chronic Myeloid Leukemia cells (K562) by a third (44). Combined with Imatinib, these 
effects on blood and bone marrow remained consistent but decreased leukemia cells by 
two-thirds (44). Further analysis showed increasing rates of cell death correlated with 
increasing doses of IBR-2 and decreasing levels of Rad51 protein (44). Protein levels of 
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Bcl-xL remained consistent, indicating that IBR-2 did not induce cell death through this 
anti-apoptotic regulator (44). 
 
Gene therapy 
This following study by Cao, et al., explored gene therapy to directly target a 
toxin to a specific Rad51 promoter, Rad51C. This novel experimental therapy involved 
the viral delivery of diphtheria toxin A in order to decrease protein levels of Rad51C. 
Comparison of normal cell lines to 4 breast cancer cells HCC1954, MCF-7, T47D, and 
MDA-MB-231, cervical cancer (HeLA), kidney cancer (GP2-293), and fibrosarcoma 
(HT1080) showed that cancer cells had 6 times the amount of Rad51C mRNA and 10 
times the amount of Rad51C protein while other proteins such as Rad51B and Rad51D 
did not show statistically significant elevation (5). Cloning a fragment of the promoter 
with luciferase or GFP visually demonstrated that these fragments specifically targeted 
cancer cells and these cancer cells showed a 200-fold increase in Rad51C activity (5). 
Gene therapy results showed that the promoter fusion of Rad51C to diphtheria toxin A 
decreased cancer cell survival down to about 10% without significantly affecting regular 
cells which showed 90% survival (5). Similar to the varying levels of Rad51C 
expression, Rad51C levels decreased up to 10 times with variance between different 
cancer cell lines but did not significantly affect regular cell lines (5). Although this 
technique was effective at reducing levels of Rad51C and decreasing survival, it was not 
effective for all cancer lines. Breast cancer cell line (HCC1954) had 50% survival while 
HeLA and GP-293 breast cancer lines had 20% survival (5). 
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Discussion 
Erlotinib  
The study of Erlotinib on head and neck squamous cell carcinoma (SCC) and 
non-small cell lung cancer (NSCLC) indicated that epidermal growth factor receptors 
(EGFR) and EGFR inhibitors play important roles in cancer therapy. The in-vitro studies 
showed that radiotherapy alone was most effective for treating both SCC and NSCLC 
since it resulted with the lowest cell survival. However, addition of Erlotinib to 
radiotherapy decreased cell survival in an additive manner, which supported Erlotinib’s 
role as a radiosensitizer. This radiosensitizing effect was supported by the fact that 
Erlotinib prevented radiotherapy induced Rad51 expression, indicating that Erlotinib 
achieved its effect by preventing an elevation in this HR repair protein. Exposure to 
different doses of radiation showed that Erlotinib moderately improved radiation 
response by a maximum of 40%. A 40% improvement in radiation response applied to 
conventional radiotherapy could significantly improve patient outcomes and survival 
rates. Not to mention, this may allow for more tolerable radiation dosing regiments by 
decreasing the dose applied but still maintaining high efficacy.  
Improvements in outcomes and survival were supported and demonstrated by 
mouse xenograph studies. These in-vivo studies showed that radiation therapy was most 
effective at decreasing tumor volume by a half but also provided evidence showing that 
Erlotinib with radiation therapy maximized tumor shrinkage by 75%. 
Immunofluorescence studies of in-vivo tissue showed that Erlotinib with radiation 
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therapy was superior at suppressing tumor proliferation and EGFR markers compared to 
monotherapy or controls.  Tumor shrinkage and suppression of these markers provided 
strong evidence to support in-vitro studies but also demonstrated that the results were not 
just due to action on Rad51.  
There were some weaknesses in this study that decrease the ability to interpret the 
link between Rad51 expression and treatment outcomes. For example, there was a lack of 
Rad51 protein quantification. Quantifying levels of Rad51 protein would allow for 
analysis of statistical correlation to radiosensitization, tumor survival, and tumor volume. 
Although this study did not identify the mechanism between upstream inhibition of 
EGFR receptors and downstream effects on Rad51 expression, a recent study indicated 
that Erlotinib inhibition of EGFR receptors suppressed downstream Mek/Erk and AKT 
kinase pathways which prevented the interaction of insulin receptor substrate 1 (IRS1) to 
Rad51 thereby inhibiting HR repair (39).  
Despite those weaknesses, the in-vitro and in-vivo studies highlight the 
importance Rad51 suppression and its role on radiosensitization, tumor survival, and 
tumor shrinkage. The study also supported the addition of Erlotinib to conventional 
radiotherapy due to improved efficacy and therapeutic response. All of these factors 
could lead to improved patient survival and outcomes. Overall, the effect of Erlotinib on 
Rad51 suppression support combination therapy and further studies into Rad51 
inhibitors. 
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Imatinib 
Similar to Erlotinib, Imatinib is also a tyrosine kinase inhibitor. The difference is 
that Imatinib inhibits c-ABL, which is responsible for increased Rad51 expression and is 
upregulated in certain cancers. Use of Imatinib in prostate adenocarcinoma, pancreatic 
adenocarcinoma, bladder carcinoma, and human lung carcinoma showed that decreasing 
Rad51 protein by half limited HR repair to 30% of normal function. Tests of cell survival 
showed that combination therapy such as Imatinib with radiation or Imatinib with 
chemotherapy (Mitomycin C or Gemcitabine) was significantly more effective in 
decreasing cell survival than monotherapy without affecting regular cells. While Erlotinib 
increased apoptosis, decreased cell survival by Imatinib was due to mitotic catastrophe. 
In-vivo studies using pancreatic adenocarcinoma indicated that Imatinib with radiation 
was superior at increasing the delay in tumor growth compared to monotherapy without 
changes in gut toxicity. 
The quantification of Rad51 protein levels and its relationship to HR repair 
efficacy is quite useful for determining how much Rad51 inhibition can improve 
conventional therapies. In-vitro studies provided statistically significant data favoring the 
use of Imatinib with either radiation or chemotherapy rather than use these conventional 
therapies alone or without the action of Imatinib on Rad51 levels. It is important to 
highlight that Imatinib decreased tumor survival without significantly affecting the 
normal fibroblast cells. This suggests that Imatinib has the ability to improve response 
without impairing or harming regular tissue. In-vivo prostate adenocarcinoma xenographs 
supported this claim since mice exposed to Imatinib and radiation had comparable weight 
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and gut tissue to mice that were exposed to radiation only. Although in-vivo data did not 
indicate the magnitude of Imatinib as a radiosensitizer or how much it could affect tumor 
volume like the Erlotinib study, the data does support use of Imatinib with radiation since 
it significantly delayed the return of tumor to its previous untreated volume. Reduced 
tumor growth may allow for clinicians to use different strategies for treating cancer. 
Other studies could be performed to analyze the ability of Imatinib to shrink tumor 
volumes compared to other therapies along with using different tissue xenographs in 
order to compare efficacy. 
Most interestingly, the data indicated that use of siRNA for Rad51 protein showed 
that HR repair was maximally functional at 70% while Imatinib showed maximum 
efficacy at 30%. It appeared that Imatinib was much more effective than siRNA 
targeting. This is quite unlike the mouse glioma experiments, which demonstrated much 
higher efficacy using antisense oligonucleotides. It would be of interest to see if siRNA 
could be another way to inhibit Rad51 levels and to test how it affects HR repair efficacy 
and chemo or radiosensitivity in other cell lines. Other interesting data showed that 
Imatinib decreased cell survival through mitotic catastrophe while Erlotinib decreased 
cell survival through increased apoptosis. Nature Reviews indicated that mitotic 
catastrophe is part of a non-apoptotic pathway (26). Although both are tyrosine kinase 
inhibitors with different targets and show a shared similarity in decreasing Rad51 
function, there is no clear indication why use of these drugs led to different cell death 
pathways. Further analysis identifying this mechanism could lead to improved targeting 
of cancer cells.  
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Regardless of these interesting data generated by the study, analysis of the 
majority of the study indicated that Imatinib showed great applicability in a wide variety 
of cancer types. These different types of cancers responded well to chemotherapy and 
radiotherapy upon inhibition of Rad51 protein levels. In-vivo studies showed delayed 
tumor growth and comparable gut toxicity, which could aid health professionals in 
developing treatment plans along with improving prognosis and quality of life. Overall, 
the data supported the use of Imatinib and inhibition of Rad51 as a chemosensitizer and 
radiosensitizer with a favorable safety profile.  
Panobinostat 
While Erlotinib and Imatinib targeted tyrosine kinase activity to affect 
downstream mediators of Rad51 expression, Panobinostat is a histone deacetylase 
inhibitor (HDACi) that interferes with the ability of Rad51 to bind to sites of DSBs by 
affecting its access to chromatin by modifying histone properties. Results showed that 50 
nanomolar and greater doses of Panobinostat alone downregulated Rad51 and HR repair 
signaling proteins in bladder carcinoma cell lines, decreasing cell survival down to about 
20%. Rad51 knockout lines showed greater survival than bladder carcinoma lines, 
indicating that interfering with chromatin access affected factors other than Rad51. 
Identification of this mechanism may allow for improved targeting and drug design to 
take advantage of decreased tumor survival. Interestingly NHEJ deficient cell lines were 
most affected by Panobinostat. This indicates that patients with NHEJ deficient bladder 
cancers would benefit the most from Rad51 inhibition or Panobinostat.  
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Tests of radiosensitivity showed that 25 nM doses of Panobinostat with radiation 
decreased cell survival to around 10%, which was comparable to Rad51 knockout lines 
while NHEJ deficient lines showed less than 10% survival. Delayed formation of γH2AX 
foci indicated that Panobinostat increased DSBs and delayed its repair. Compared to 
controls, these results indicated that use of Panobinostat and inhibition of Rad51 function 
doubled the effectiveness of radiotherapy. Being able to double the effectiveness of 
radiotherapy might benefit patients by allowing more tolerable radiation doses or 
regiments, possibly decreasing tissue damage and risk of creating new malignancies. This 
could improve access for older patients since treatment guidelines for bladder carcinoma 
call for an initial dose of chemotherapy followed by surgery, radiotherapy or a 
combination of chemo- and radiotherapy, and both surgery and radiotherapy have similar 
results and are not well tolerated (18).  
Although this study demonstrated the effect of Panobinostat as a radiosensitizer, 
there was no indication whether or not it would also hold true as a chemosensitizer as 
seen from the Imatinib study. It would be interesting to perform an analysis of whether 
Panobinostat is a better radiosensitizer or chemosensitizer. Quantification of Rad51 
protein levels, HR repair assays, and histone folding could also provide deeper insight as 
to the degree of changes required to have an overall impact on cell survival. This data 
could be compared to other HDACi and other types of cancers with upregulated histone 
deacetylase activity in order to determine how to produce the best outcomes. 
Additionally, it would have been interesting to see how Panobinostat affects in-vivo 
bladder carcinoma xenographs and whether or not it would be tolerable. These data could 
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reveal great insights into the applicability of Panobinostat and histone modification as a 
means to inhibit Rad51 and improve conventional therapeutics. In conclusion, this study 
was the first to identify the role of Panobinostat as a radiosensitizer in bladder carcinomas 
through inhibition of Rad51 and HR repair function by novel means of histone 
modification.  
 
SAHA 
Another HDACi that has shown efficacy in some studies is Suberoylanilide 
Hydroxamic Acid (SAHA). SAHA is used for certain cancers such as T-cell lymphoma. 
Further review of this drug revealed that changes in chromatin induced by targeting 
histones correlated a threefold decrease in Rad51 protein with decreased cell survival. 
This is supported by data from Figure 5B (page 32) which showed that increased 
acetylation increased histone folding, leading to increased cell death compared to 
untreated controls at all radiation doses. Although levels of Rad51 protein were 
decreased, this histone modification also prevented the remaining Rad51 proteins from 
accessing the DSBs. This effect was seen and consistent in 4 different human multiple 
myeloma cell lines. While HR repair assay data showed that SAHA specifically targeted 
HR repair, it appeared that siRNA was more effective at inhibiting HR repair. These 
results are opposite of the Imatinib study, indicating that it might be due to cancer 
specific differences or due to targeting different mechanisms. Other studies could be 
performed with identical cell lines, siRNA inhibitors of Rad51, and same medication, 
Imatinib and/or SAHA, to identify which method is the most efficacious. Overall, these 
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data demonstrated the mechanism and radiosensitizing effects of SAHA and provide 
support for its use in convention therapies.   
Although the study demonstrated significant evidence supporting the use of 
radiotherapy combined with SAHA as a Rad51 inhibitor, the authors did not test the 
effect of Rad51 inhibition of chemotherapeutic agents. Chemotherapeutic agents can also 
induce DSB and it would be interesting if future studies tested and compared different 
therapy regiments: chemotherapy alone, radiotherapy alone, chemotherapy and 
radiotherapy combined, chemotherapy and SAHA combined, radiotherapy and SAHA 
combined, or a combination of all 3 treatments.  The ability for SAHA to inhibit HR 
repair and radiosensitize should yield similar results with other techniques that can 
introduce DSB. Other studies such as the Imatinib review mentioned previously have 
indicated that inhibition of Rad51 mediated HR repair does result with increased 
chemosensitivity. However, these studies have not examined the combination of 
combined chemoradiotherapy verses combined chemoradiotherapy + Rad51 inhibitor. 
Such studies may reveal which is the most appropriate for clinical use and best patient 
outcomes. Future clinical studies should also test to see if SAHA reduced toxicity can be 
used to decrease radiotherapy or chemotherapy doses while maintaining high efficacy. 
This may be a more efficient and effective method for improving patient outcomes, 
quality of life, and 5-year survival rates.  
 
Methotrexate 
A study designed to understand how Methotrexate interfered with HR repair in 
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osteosarcoma revealed the unusual link between tetrohydrofolate depletion and specific 
depletion of Rad51 mRNA. HR repair assay data showed that Methotrexate doubled 
radiation induced DNA damage and decreased repair efficacy by half compared to 
controls. These Methotrexate treated lines showed complete lack of antibody staining for 
Rad51 protein, indicating that Methotrexate was very successful at inhibiting Rad51 
function and prevented the radiation induced production of Rad51 protein which lowers 
therapeutic efficacy and increases risk of metastasis. Although Methotrexate is a DNA 
synthesis inhibitor, quantification of Rad51 mRNA levels showed a 100% decrease but 
did not significantly affect other mRNA transcripts such as BRCA2 or Rad52. This data 
revealed the odd novelty of Rad51 protein levels being linked with DNA synthesis, 
raising the question of why Rad51 was specifically targeted yet other mRNA transcripts 
were not. Identifying this link could led to better methods of inhibiting Rad51 function 
along with potentially targeting other proteins linked to cancer progression. The fact that 
this data showed decreased colony formation from Methotrexate treated cells supports the 
role of Rad51 inhibition in decreasing metastasis.  
Future studies could be done to improve analysis of this study and other 
previously reviewed studies. For example, analysis of Methotrexate action on cell cycle 
distribution could illuminate whether or not Rad51 depletion was due to a decreased 
fraction of cells in S phase. As mentioned earlier, Rad51 is highly active in the G1/S 
phase and the S phase is likely targeted by Methotrexate. However, this alone does not 
explain the data showing that other mRNA transcripts were relatively unaffected. Other 
experiments could be performed for deeper analysis of Methotrexate inhibition of HR 
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repair by comparing radiotherapy cell survival of treated lines to untreated lines. This 
data could quantify the link between HR repair efficacy, DNA damage, and cell survival. 
Cell survival assays using untreated controls, treated normal cells, and treated malignant 
cells might indicate best dosage for targeting Rad51 without adversely decreasing other 
mRNA transcripts. Combined with further radiosensitivity and additional 
chemosensitivity tests could reveal optimal strategies for combating cancer proliferation 
along with yielding valuable data for future therapies. To summarize, this study of 
Methotrexate applied to human osteosarcoma cell lines has revealed the novel link 
between inhibition of DNA synthesis and targeted Rad51 depletion, generating more 
questions and avenues to explore in improving cancer therapeutics. 
 
Experimental Rad51 Inhibitors 
 Although Erlotinib, Imatinib, Panobinostat, SAHA, and Methotrexate are 
currently used therapeutics that have recently been discovered to affect upstream and 
downstream factors involved in Rad51 protein levels, researchers have now turned their 
focus onto experimentally targeting Rad51 function. One of these is an experimental 
drug, IBR-2, and the other involves gene therapy.  
 
IBR-2 
IBR-2 is a drug designed to overcome Imatinib resistance due to overexpression 
of Bcr-abl, the target of Imatinib, which directly contributes to Rad51 overexpression. As 
a result, targeting Rad51 protein was necessary since Rad51 overexpression leads to 
adverse effects such as resistance to chemotherapy and radiotherapy, increased tumor 
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survival, and metastasis. Data from the study showed that IBR-2 alone was successful at 
inhibiting HR repair and IBR-2 with radiation doubled the efficacy of radiotherapy, 
which adversely affected colony survival. These survival results were similar to 
Methotrexate but not as potent as the cell survival results from Erlotinib or Panobinostat 
but are difficult to directly compare due to use of different cell lines. 
Analysis of Rad51 levels showed that Rad51 mRNA was not affected while 
Rad51 protein levels were decreased and the protein was prevented from interacting with 
DSBs. Dose response studies provided inverse correlation between IBR-2 and Rad51 
protein levels. Data showed that other protein levels were unaffected, indicating Rad51 
specific targeting, which could reduce side effects on in-vivo studies along with 
providing clearer interpretation of Rad51 interaction. Use of a proteasome inhibitor 
showed the novel effect of how Rad51 proteins undergo accelerated breakdown due to 
IBR-2 inhibition of Rad51 protein assembly. It is unclear if other drugs that prevent 
Rad51 assembly or association with DSBs also undergo accelerated proteasome 
breakdown. Since Panobinostat and SAHA also prevent Rad51 association with DSBs, 
addition of a proteasome inhibitor and protein analysis to these studies could indicate 
whether or not this effect was due to IBR-2 action or due to prevention of Rad51 
association with DSBs. Taking advantage of this mechanism could prevent the radiation 
induced increase of Rad51 levels seen after radiotherapy exposure. 
In-vitro studies on leukemia and 4 different aggressive breast cancer cell lines 
showed that this Rad51 inhibitor was successful at increasing cell death, reducing growth, 
and could be used in a wide variety of cancers. Due to Rad51 specific targeting, the 
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authors conducted in-vivo studies and wide variety of tolerability tests using Chronic 
Myeloid Leukemia lines, which are Imatinib resistant. The in-vivo tests showed highly 
successful results, with both IBR-2 and Rad51 RNAi decreasing tumor volume by 75%. 
Tests comparing IBR-2 to Rad51 RNAi are critical for evaluating the effectiveness of 
IBR-2 inhibition of Rad51 and these tests showed that the results were equivalent. It was 
interesting to see that IBR-2 with Imatinib decreased cell survival by an additional third, 
indicating that IBR-2 overcame Imatinib resistance and rendered the drug useful again.  
 This combination of IBR-2 with Imatinib highlighted the idea that a Rad51 
inhibitor by itself, although highly effective in this scenario, might demonstrate greater 
effectiveness with other therapeutics that target Rad51 and/or other signaling pathways. 
Although the authors indicated that increasing doses of IBR-2 correlated with decreased 
Rad51 protein, there were no indications of whether or not IBR-2 with Imatinib 
decreased Rad51 even further. These results would be necessary for determining if the 
mechanism for overcoming Imatinib resistance was due to other factors, such as 
signaling, or due to greater impairment of Rad51 function. These data could allow 
researchers to determine if complete suppression of Rad51 protein is necessary or if 
targeting multiple Rad51 pathways would lead to improved efficacy. 
Further tests indicated high tolerability without side effects since IBR-2 did not 
affect normal blood cells, bone marrow cells, or mice weight. Other reviewed studies 
used normal fibroblasts, mice weight, or histological examination of gut tissue to test for 
toxicity. The use of normal blood cells and bone marrow cells appeared to be unique 
compared to the other studies and provided valuable data for the next step in research. 
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Future tests involving Rad51 inhibition as a chemosensitizer or radiosensitizer should 
include normal hematological cells as controls for tolerability testing along with the 
commonly use fibroblasts. These data would be useful for in-vivo studies and human 
application should it reach that stage. 
These results, along with radiosensitivity data, support the use of IBR-2 as a 
supplement to improve conventional therapies. Overall the data suggest that IBR-2 was 
successful at improving chemotherapy and radiotherapy response in a variety of cancer 
types and was highly effective at overcoming in-vivo drug resistance without side effects, 
thus providing support for future studies in other types of cancers. 
 
Experimental Gene Therapy 
The experimental gene therapy study provided novel data that may lead to 
improved Rad51 targeting. This study showed that a specific promoter, Rad51C, showed 
between 6 to 10 times elevation of Rad51C mRNA or protein in 4 different breast cancer 
lines, cervical cancer, kidney cancer, and fibrosarcoma. This study was the first to 
indicate this subtype of Rad51 is significantly elevated in multiple types of cancers, 
thereby providing a potentially useful target. The use of a diphtheria toxin A poison fused 
to this Rad51C promoter in all of these cell lines resulted in higher efficacy than 
Erlotinib, Imatinib, Panobinostat, SAHA, Methotrexate, or IBR-2 by only allowing on 
average, 10% cancer cell survival yet allowing 90% of normal cells to remain viable. 
These results demonstrated the potential of targeting a more specific subtype of Rad51 
protein that is unusually elevated in a wide variety of cancers, many of which were the 
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same lines used in those other studies.  
However effective this therapy appeared, one breast cancer line showed 50% 
survival while cervical and another breast cancer line showed 20% survival. These data 
demonstrate that although Rad51C may have the broadest applicability in wide varieties 
of cancers, certain cancer subtypes show some individual variance to Rad51C targeting. 
This was similar to discrepancies within the other reviewed studies. Future studies of 
gene therapy and other drugs that target Rad51 should test for effect in more cancer lines 
and cancer subtypes to determine if Rad51 targeting has an even broader applicability 
than demonstrated. Considering that this study was very novel, it is possible that 
therapies designed to inhibit Rad51C protein may vastly improve its use with 
conventional chemotherapy or radiotherapy. The ability to deliver a poison to Rad51C 
elevated cancer cells combined with a general Rad51 inhibitor and conventional therapies 
may future decrease cancer survival to below 10%, which could result with massively 
improved outcomes and cell survival. It may even be advantageous to examine whether 
or not other highly elevated proteins in cancers are viable targets for this type of gene 
therapy. In conclusion, this gene therapy study provided valuable evidence for a new 
method of attacking cancer cells along with potentially improving conventional therapies. 
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Conclusion 
The data from studies of HR repair suggested that targeting this process could 
lead to efficacy improvements in cancer therapies. Investigation into that line of 
reasoning revealed that Rad51 was highly elevated in multiple types of cancers and 
cancer subtypes, encompassing cervical carcinoma, many breast cancers, esophageal 
squamous cell carcinoma, lung cancer, colorectal cancer, and many hematological 
malignancies. Early studies showed that suppressing Rad51 function greatly improved 
radiosensitivity and chemosensitivity. Numerous studies to determine the value of Rad51 
expression as a prognostic indicator showed that overexpression of Rad51 was usually 
seen in patients with aggressive carcinomas. In-vivo studies by Wiegmans, et al., using 
different cancer lines, provided crucial data indicating that Rad51 greatly influenced 
tumor growth and progression and was required for metastasis to distal organs (42).  
As a result of the mounting evidence showing the role of Rad51 in cancer, many 
authors revisited commonly used therapeutics with the goal of determining whether or 
not Rad51 was a critical part of the mechanism. Their data revealed that the 
radiosensitizing effects caused by Erlotinib, Imatinib, Panobinostat, SAHA, and 
Methotrexate were due to impairment of Homologous Recombination repair through 
interference with Rad51 function. Although it was critical to identify the role of Rad51 in 
decreasing cancer growth and progression, these studies also provided valuable data 
showing that suppression of Rad51 function could vastly improve chemotherapy and 
radiotherapy efficacy in a vast variety of cancers.  
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From these successful results, other authors started focusing on ways to target 
Rad51 function more efficiently by performing screening for inhibitors of this protein. 
This led to an experimental inhibitor known as IBR-2 to directly target the protein and 
inhibit its assembly. The data provided evidence that the drug was successful at Rad51 
inhibition in many types of blood cancers. What was most interesting was that it even 
overcame therapeutic resistance and improved therapeutic response with other 
chemotherapeutics. Other studies discovered that a highly expressed form of Rad51, 
known as a Rad51C paralog, was even more elevated in broad varieties of cancers. The 
viral delivery of diphtheria toxin A bound to a Rad51C promoter represented new insight 
on Rad51 but also introduced a new way of targeting overexpressed Rad51 in cancer 
cells. These early results demonstrated even greater cancer cell death compared to 
existing therapeutics that interfered with Rad51 or the experimental IBR-2 drug.  
Given the evidence showing that Rad51 targeting could improve chemosensitivity 
and radiosensitivity, it was enlightening to review articles that reexamined existing drugs 
and demonstrated the role that these drugs had on improving conventional therapies 
through Rad51 targeting. The arching theme of these reviews suggested that Rad51 is a 
viable target, along with having value as diagnostic and prognostic factors, in wide 
varieties of cancers and are applicable at improving chemotherapy or radiotherapy both 
in-vitro and in-vivo. However, tests of cell survival, cell growth, chemosensitivity, 
radiosensitivity, tumor shrinkage, and side effects all have wide variance between studies 
and within studies, making it very difficult to make a unified conclusion. Of note is that 
very few studies tested for chemosensitivity even though chemotherapeutics also induce 
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DSB and Rad51 inhibition and impair DSB repair. It is clear from the data that the 
studies differ in design, which makes it difficult to compare drugs and cancer lines that 
are of the same category, which would require complex analysis and changes to studies to 
make an accurate conclusion. Future analysis may require additional inclusion of Rad51 
testing and standardization of how Rad51 targeting is tested. Since the radiosensitizing 
mechanisms from Rad51 suppression in existing therapeutics were recently discovered 
and demonstrated in new studies, it is possible that the lack of testing for this protein may 
have confounded the results of previous studies. Additional studies and testing of Rad51 
would benefit reviews of past and future studies of radiosensitizers and chemosensitizers, 
which may require accounting for Rad51 action on inhibiting DSB repair. Experimental 
therapeutics showed great results from targeting Rad51 function or using overexpression 
of Rad51 as a target for poisons, which increases the value of investigating techniques for 
targeting Rad51. Despite the varying data and differences in acquiring these data, there is 
general evidence that indicate use of a Rad51 inhibitor should be included with 
conventional therapies due overexpression of Rad51 levels in many different types of 
cancers, the influential roles of affecting growth rate along with permitting metastasis, 
and the ability for improvement in chemosensitivity and radiosensitivity without 
significant side effects.  
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